Kamada Issues 2023 CEO Letter to Shareholders
March 15, 2023 07:10 ET
|
Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed...
Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth
March 15, 2023 07:00 ET
|
Kamada Ltd.
Total Revenues for Fiscal Year 2022 of $129.3 Million Represented Growth of 25% Compared to Fiscal Year 2021; Fourth Quarter 2022 Revenues of $45.4 Million Represented a 44% Increase...
Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023
March 09, 2023 08:00 ET
|
Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products...
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel
January 04, 2023 07:00 ET
|
Kamada Ltd.
FDA Approval Currently Expected by Mid-2023Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50%Ability to Manufacture CYTOGAM at Kamada’s Facility...
Kamada Announces Planned Transition of Chief Financial Officer
December 19, 2022 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty...
Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance
November 22, 2022 07:00 ET
|
Kamada Ltd.
Third Quarter 2022 Revenues of $32.2 Million, a 40% Increase Compared to Prior Year Period; Reaping the Benefits of the Acquired IgG PortfolioStrong Results Represent Completion of the Company’s...
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022
November 16, 2022 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty...
Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT
November 07, 2022 07:00 ET
|
Kamada Ltd.
Trial Recruitment Beginning to Accelerate; 30 Patients Enrolled and Treated to DateIndependent Data Safety Monitoring Board (DSMB) Recommends Study Continuation Without Modification for Fourth Time...
Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference
October 26, 2022 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty...
Kamada Awarded $22 Million Extension of Canadian Supply Tender
October 19, 2022 07:00 ET
|
Kamada Ltd.
Awarded Extension to Existing Supply Tender which relates to Portfolio of Four Specialty IgG Products Acquired in 2021Supply Extension Secures Ongoing Sales of Approximately $7.5 Million Per Year for...